



Engineered Immunotherapy for Cancer

Cancer Progress, NY
March 9, 2016

www.adura.com

Disclaimer

Special Note Regarding Forward-Looking Statements

This presentation and the accompanying oral presentation include express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of Aduro Biotech, Inc. ("Aduro") that are not historical facts. These forward-looking statements include statements regarding Aduro's expectations for its product candidates (including their therapeutic and commercial potential, anticipated future development activities, anticipated timing of development activities, the indications Aduro and its collaborators plan to pursue, anticipated submissions to the U.S. Food and Drug Administration, potential for eventual regulatory approval, commercialization and launch of Aduro's product candidates), future results of operations and financial position, business strategy, strategic collaborations, any royalty or milestone payments and Aduro's ability to obtain and maintain intellectual property protection for its product candidates. Such forward-looking statements may be identified by words such as "believes", "may", "will", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should", "objective" and variations of such words and similar words. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, Aduro's history of net operating losses and uncertainty regarding its ability to achieve profitability, Aduro's ability to develop and commercialize its product candidates, Aduro's ability to use and expand its technology platforms to build a pipeline of product candidates, Aduro's dependence on its lead product candidate, CRS-207, and GVAX Pancreas, Aduro's ability to obtain and maintain regulatory approval of its product candidates, Aduro's inability to operate in a competitive industry and compete successfully against competitors that have greater resources than it does, Aduro's reliance on third parties, and Aduro's ability to obtain and adequately protect intellectual property rights for its product candidates. Aduro discusses many of these risks in greater detail under the heading "Risk Factors" contained in its most recent Quarterly Report on Form 10-Q which is on file with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Aduro's actual results of operations, financial condition and liquidity, and the development of the industry in which Aduro operates, may differ materially from the forward-looking statements contained in this presentation and the accompanying oral presentation. Any forward-looking statements that Aduro makes in this presentation and the accompanying oral presentation speak only as of the date of these presentations. Except as required by law, Aduro assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date hereof.

Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Aduro or any director, employee, agent, or adviser of Aduro. This presentation does not purport to be all-inclusive or to contain all of the information you may desire.


The content of this presentation is subject to copyright, which will be asserted by Aduro, and no part of this presentation may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without prior permission in writing from Aduro.

Aduro Highlights



- Three diverse and versatile immunotherapy platforms
 - **LADD** – novel, live-attenuated *Listeria* platform to deliver tumor antigens
 - Survival benefit demonstrated in randomized Phase 2 trial in pancreatic cancer trial
 - 94% disease control rate in Phase 1b mesothelioma trial
 - Two Phase 1 trials in lung and prostate cancer underway by Janssen Pharmaceuticals
 - Phase 1/2 trial in ovarian cancer planned in collaboration with Incyte
 - **STING Pathway Activators**– small molecule immune modulators
 - Major oncology collaboration with Novartis
 - Phase 1 trial in accessible tumors planned
 - Maintain rights in all ex-oncology areas, including autoimmune and infectious diseases
 - **B-select mAbs** – acquired proprietary technology and preclinical assets
 - Multiple checkpoint inhibitors and receptor-activating agonists
- Strategies for monotherapies and combination regimens
- Strong financial and IP position

LADD Platform

Stimulates Innate Immunity Responses and Antigen-specific T Cell Responses




ADU-S100 Activate Innate & Adaptive Immunity through STING Pathway



B-select Monoclonal Antibodies

Targets First- or Best-in-Class Agonist and Antagonist mAbs



Enhancing Therapeutic Strength through Combinations

Breadth of Potential Combinations with Conventional and Novel Therapies

